GlassScriptPhysician profile
Bradley L Shoss
NPI 1013203272
$4,273.47
in general payments reported to CMS, 2019-2025
21 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $148 · 2021: $533 · 2022: $406 · 2023: $1,375 · 2024: $489 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.09 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,424.66 | 2019-2025 | Centurion, Clareon, Argos |
| Abbvie INC. | $544.12 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Glaukos Corporation | $533.83 | 2019-2025 | Ce-Marked Kxla System, Photrexa, Istent Infinite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $324.37 | 2019-2021 | |
| Rxsight INC | $214.54 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $204.34 | 2024-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $196.50 | 2023 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Harrow Eye, LLC | $159.60 | 2024-2025 | Vevye, Triesence |
| Regeneron Healthcare Solutions, INC. | $117.00 | 2022 | |
| Oyster Point Pharma, INC. | $105.51 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $95.79 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $93.13 | 2019 | |
| Amgen INC. | $54.92 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $42.32 | 2021 | |
| Allergan, INC. | $38.62 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $37.77 | 2023-2024 | Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $26.60 | 2020-2021 | |
| Shire North American Group INC | $22.12 | 2019 | |
| Horizon Therapeutics Plc | $14.62 | 2023 | Tepezza |
| Pacira Pharmaceuticals Incorporated | $13.84 | 2025 | Exparel |
| Biotissue Holdings INC. | $9.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Shoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.